“Personalized” battle against GI cancers: ASCO GI 2024 highlights
Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront. While immunotherapy has made a transformational impact in many areas, it hasn’t seen the same success in GI cancers. This has led to rising recognition of cancer heterogeneity and highlighting the need for personalization for therapeutic benefit in subpopulations.
The key highlights at ASCO GI 2024 resonated with the theme of ‘Taking Personalized Care to the Next Level’ and provided a glimpse into the future of personalized medicine for GI cancers. Discover the post-conference takeaways from Inizio Advisory here.
Here’s how we help to shape the future of oncology treatments.
Jump to a slide with the slide dots.
AI without limits: A smarter, integrated approach to Medical Affairs
Let’s get one thing clear: AI is not here to replace Medical Affairs professionals.
Read moreAI with intent: How Inizio is redefining pharma through precision and partnership
Discover how Inizio is harnessing AI with intent to redefine pharma and progress across the healthcare landscape.
Read more
Richard Lawrence
Achieving quality, reach, speed and efficiency in Medical Affairs
The pharmaceutical industry is in a constant state of change, driven by shifting demands and increasing complexity. Within this evolving landscape, th
Read more